MS Speaks

Multiple Sclerosis => TREATMENTS => Topic started by: agate on July 17, 2018, 02:21:23 pm

Title: (Abst.) Drug-associated PML in MS patients
Post by: agate on July 17, 2018, 02:21:23 pm
From Multiple Sclerosis Journal, July 9, 2018--"Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients," a study of more than 100,000 MS patients over two years (2015-17).  The researchers conclude:



Quote
The relative risk of PML with natalizumab was much higher than with any of the other DMDs and one with fingolimod followed. One with dimethyl fumarate and rituximab was lesser. Glatiramer acetate, interferon, and dalfampridine were not associated with PML risk based on our analysis.


http://journals.sagepub.com/doi/abs/10.1177/1352458518786075